Examining the Pathogenesis of Breast Cancer Using a Novel Agent-Based Model of Mammary Ductal Epithelium Dynamics

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Chapa, Joaquin ^a   Bourgo, Ryan J ^b   Greene, Geoffrey L ^b   Kulkarni, Swati ^b   An, Gary ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; MYC PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR RUNX3;

ARTICLE; BREAST CANCER; BREAST DUCT; BREAST EPITHELIUM; CANCER INCIDENCE; CARCINOGENESIS; CARCINOGENICITY; CELL DIVISION; CELL FUNCTION; CELL LINE; CELL POPULATION; DNA DAMAGE; DNA REPAIR; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE MUTATION; GENETIC ASSOCIATION; GENOME; HORMONE RELEASE; HUMAN; INHERITANCE; MATHEMATICAL MODEL; MENSTRUAL CYCLE; ONCOGENE; PREGNANCY; SIGNAL TRANSDUCTION; SIMULATION; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

BRCA1 PROTEIN; BREAST NEOPLASMS; CALIBRATION; CELL CYCLE; COMPUTER SIMULATION; DNA DAMAGE; DNA REPAIR; EPITHELIUM; FEMALE; HUMANS; MAMMARY GLANDS, HUMAN; MODELS, BIOLOGICAL; MUTATION; NEOPLASM PROTEINS; RECEPTORS, ESTROGEN;

EID: 84877991231     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064091     Document Type: Article

References (108)

1. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
2. Polyak K, (2007) Breast cancer: origins and evolution. J Clin Invest 117: 3155-3163.
3. Vodovotz Y, Csete M, Bartels J, Chang S, An G, (2008) Translational systems biology of inflammation. PLoS Comput Biol 4: e1000014.
4. Kaiser MI, (2011) The limits of reductionism in the life sciences. Hist Philos Life Sci 33: 453-476.
5. An G, (2001) Agent-based computer simulation and sirs: building a bridge between basic science and clinical trials. Shock 16: 266-273.
6. Bonabeau E, (2002) Agent-based modeling: methods and techniques for simulating human systems. Proc Natl Acad Sci U S A 99Suppl 3: 7280-7287.
7. An G, Mi Q, Dutta-Moscato J, Vodovotz Y (2009) Agent-based models in translational systems biology. Wiley Interdisciplinary Reviews: Systems Biology and Medicine.
8. Grimm V, Revilla E, Berger U, Jeltsch F, Mooij W, et al. (2005) Pattern-oriented modeling of agent-based complex systems: Lessons from ecology. Science 310: 987-991.
9. Wilensky U, Rand W (2009) An introduction to agent-based modeling: Modeling natural, social and engineered complex systems with NetLogo. Cambridge, MA: MIT Press.
10. Berg JW, Hutter RV, Percy C, Young JL Jr, Muir C, (1995) Histology of cancer incidence and prognosis: SEER Population-Based Data, 1973-1987. Cancer 75: 139-421.
11. Visvader JE, (2009) Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 23: 2563-2577.
12. Kim C, Paik S, (2010) Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol 7: 340-347.
13. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
14. Kao KJ, Chang KM, Hsu HC, Huang AT, (2011) Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11: 143.
15. Correa Geyer F, Reis-Filho JS, (2009) Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? Int J Surg Pathol 17: 285-302.
16. Place AE, Jin Huh S, Polyak K, (2011) The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res 13: 227.
17. Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, et al. (1999) Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 155: 1811-1815.
18. Soderqvist G, von Schoultz B, Tani E, Skoog L, (1993) Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. Am J Obstet Gynecol 168: 874-879.
19. Khan SA, Yee KA, Kaplan C, Siddiqui JF, (2002) Estrogen receptor alpha expression in normal human breast epithelium is consistent over time. Int J Cancer 102: 334-337.
20. Umekita Y, Souda M, Ohi Y, Rai Y, Sagara Y, et al. (2007) Expression of estrogen receptor alpha and progesterone receptor in normal human breast epithelium. In Vivo 21: 535-539.
21. Taylor D, Pearce CL, Hovanessian-Larsen L, Downey S, Spicer DV, et al. (2009) Progesterone and estrogen receptors in pregnant and premenopausal non-pregnant normal human breast. Breast Cancer Res Treat 118: 161-168.
22. Sharma P, Kimler BF, Warner C, Metheny T, Xue Q, et al. (2006) Estrogen receptor expression in benign breast ductal cells obtained from random periareolar fine needle aspiration correlates with menopausal status and cytomorphology index score. Breast Cancer Res Treat 100: 71-76.
23. Chimge NO, Frenkel B (2012) The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene.
24. Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K, et al. (2009) Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta 1796: 315-331.
25. Chen LF, (2012) Tumor suppressor function of RUNX3 in breast cancer. J Cell Biochem 113: 1470-1477.
26. Huang B, Qu Z, Ong CW, Tsang YH, Xiao G, et al. (2012) RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor alpha. Oncogene 31: 527-534.
27. Nakopoulou L, Gakiopoulou H, Keramopoulos A, Giannopoulou I, Athanassiadou P, et al. (2000) c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology 36: 313-325.
28. Cheng AS, Culhane AC, Chan MW, Venkataramu CR, Ehrich M, et al. (2008) Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res 68: 1786-1796.
29. An G, (2008) Introduction of an agent-based multi-scale modular architecture for dynamic knowledge representation of acute inflammation. Theor Biol Med Model 5: 11.
30. An G, (2009) A model of TLR4 signaling and tolerance using a qualitative, particle-event-based method: Introduction of spatially configured stochastic reaction chambers (SCSRC). Math Biosci 217: 43-52.
31. An GC, Faeder JR, (2009) Detailed qualitative dynamic knowledge representation using a BioNetGen model of TLR-4 signaling and preconditioning. Math Biosci 217: 53-63.
32. Engelberg JA, Datta A, Mostov KE, Hunt CA, (2011) MDCK cystogenesis driven by cell stabilization within computational analogues. PLoS Comput Biol 7: e1002030.
33. Engelberg JA, Ropella GE, Hunt CA, (2008) Essential operating principles for tumor spheroid growth. BMC Syst Biol 2: 110.
34. Kim SH, Debnath J, Mostov K, Park S, Hunt CA, (2009) A computational approach to resolve cell level contributions to early glandular epithelial cancer progression. BMC Syst Biol 3: 122.
35. Balci O (1998) Verification, Validation and Testing. In: Banks J, editor. Handbook of Simulation: Principles, Methodology, Advances, Applications, and Practice. New York: John Wley & Sons. 335-396.
36. Balci O, (2001) A Methodology for Certification of Modeling and Simulation Applications. ACM Transactions on Modeling and Computer Simulation 11: 352-377.
37. Kennedy RC, Xiang X, Cosimano TF, Arthurs LA, Maurice PA, et al. (2006) Verification and Validation Assessment of Simulation Models. North American Computational Social and Organization Sciences (NAACSOS 2006). Notre Dame, IN: NAACSOS.
38. Stricker R, Eberhart R, Chevailler MC, Quinn FA, Bischof P, et al. (2006) Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. Clin Chem Lab Med 44: 883-887.
39. Soldin OP, Guo T, Weiderpass E, Tractenberg RE, Hilakivi-Clarke L, et al. (2005) Steroid hormone levels in pregnancy and 1 year postpartum using isotope dilution tandem mass spectrometry. Fertil Steril 84: 701-710.
40. O'Leary P, Boyne P, Flett P, Beilby J, James I, (1991) Longitudinal assessment of changes in reproductive hormones during normal pregnancy. Clin Chem 37: 667-672.
41. Lester SC (2005) The Breast. In: Kumar V, Fausto N, Robbins SL, Abbas AK, Cotran RS, editors. Robbins and Cotran Pathologic Basis of Disease. 8 ed. Philadelphia, PA: Elsievier Saunders. 1065-1096.
42. Navarrete MA, Maier CM, Falzoni R, Quadros LG, Lima GR, et al. (2005) Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle. Breast Cancer Res 7: R306-313.
43. Going JJ, Anderson TJ, Battersby S, MacIntyre CC, (1988) Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 130: 193-204.
44. Altekruse S, Kosary C, Krapcho M, Neyman N, Aminou R (2010) SEER cancer statistics review, 1975-2007. In: Institute NC, editor. National Cancer Institute. Available: http://seer.cancer.gov/csr/1975_2007/results_merged/sect_04_breast.pdf.
45. Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, et al. (2012) Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat 133: 1125-1130.
46. Easton DF, Ford D, Bishop DT, (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 265-271.
47. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, et al. (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94: 1365-1372.
48. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, et al. (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401-1408.
49. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, et al. (1999) Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 8: 741-747.
50. Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, et al. (1998) Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 63: 45-51.
51. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, et al. (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26: 4282-4288.
52. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, et al. (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26: 3324-3330.
53. Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua MG, Luini A, et al. (2012) Outcome of special types of luminal breast cancer. Ann Oncol 23: 1428-1436.
54. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, et al. (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24: 5652-5657.
55. Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, et al. (2011) Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol 29: 4373-4380.
56. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, et al. (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10: 2029-2034.
57. Tung N, Wang Y, Collins LC, Kaplan J, Li H, et al. (2010) Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res 12: R12.
58. An G, (2010) Closing the scientific loop: bridging correlation and causality in the petaflop age. Sci Transl Med 2: 41ps34.
59. Bankhead A 3rd, Magnuson NS, Heckendorn RB (2007) Cellular automaton simulation examining progenitor hierarchy structure effects on mammary ductal carcinoma in situ. J Theor Biol 246: 491-498.
60. Macklin P, Edgerton ME, Thompson AM, Cristini V, (2012) Patient-calibrated agent-based modelling of ductal carcinoma in situ (DCIS): from microscopic measurements to macroscopic predictions of clinical progression. J Theor Biol 301: 122-140.
61. Norton KA, Wininger M, Bhanot G, Ganesan S, Barnard N, et al. (2010) A 2D mechanistic model of breast ductal carcinoma in situ (DCIS) morphology and progression. J Theor Biol 263: 393-406.
62. Csete ME, Doyle JC, (2002) Reverse engineering of biological complexity. Science 295: 1664-1669.
63. Bankes SC, (2002) Agent-based modeling: a revolution? Proc Natl Acad Sci U S A 99Suppl 3: 7199-7200.
64. Rexer BN, Arteaga CL, (2012) Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog 17: 1-16.
65. Grimm V, Berger U, DeAngelis DL, Polhill JG, Giske J, et al. (2010) The ODD protocol A review and first update. Ecological Modelling 221: 2760-2768.
66. Stern JR, Christley S, Zaborina O, Alverdy JC, An G, (2012) Integration of TGF-beta- and EGFR-based signaling pathways using an agent-based model of epithelial restitution. Wound Repair Regen 20: 862-871.
67. Stern JR, Olivas AD, Valuckaite V, Zaborina O, Alverdy JC, et al. (2013) Agent-based model of epithelial host-pathogen interactions in anastomotic leak. J Surg Res.
68. Seal JB, Alverdy JC, Zaborina O, An G, (2011) Agent-based dynamic knowledge representation of Pseudomonas aeruginosa virulence activation in the stressed gut: Towards characterizing host-pathogen interactions in gut-derived sepsis. Theor Biol Med Model 8: 33.
69. Kim M, Christley S, Alverdy JC, Liu D, An G, (2012) Immature oxidative stress management as a unifying principle in the pathogenesis of necrotizing enterocolitis: insights from an agent-based model. Surg Infect (Larchmt) 13: 18-32.
70. Van Keymeulen A, Rocha AS, Ousset M, Beck B, Bouvencourt G, et al. (2011) Distinct stem cells contribute to mammary gland development and maintenance. Nature 479: 189-193.
71. Larsson O, Blegen H, Wejde J, Zetterberg A, (1993) A cell cycle study of human mammary epithelial cells. Cell Biol Int 17: 565-571.
72. Gautschi JR, Schindler R, Hurni C, (1971) Studies on the division cycle of mammalian cells. V. Modifications of time parameters by different steady-state culture conditions. J Cell Biol 51: 653-663.
73. Meyer JS, Connor RE, (1982) Cell proliferation in fibrocystic disease and postmenopause breast ducts measured by thymidine labeling. Cancer 50: 746-751.
74. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, et al. (1998) Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90: 1292-1299.
75. Clarke RB, Howell A, Potten CS, Anderson E, (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57: 4987-4991.
76. Sternlicht MD, Kouros-Mehr H, Lu P, Werb Z, (2006) Hormonal and local control of mammary branching morphogenesis. Differentiation 74: 365-381.
77. Hinck L, Silberstein GB, (2005) Key stages in mammary gland development: the mammary end bud as a motile organ. Breast Cancer Res 7: 245-251.
78. Sternlicht MD, (2006) Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis. Breast Cancer Res 8: 201.
79. Wiseman BS, Sternlicht MD, Lund LR, Alexander CM, Mott J, et al. (2003) Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis. J Cell Biol 162: 1123-1133.
80. Haslam SZ, Drolet A, Smith K, Tan M, Aupperlee M, (2008) Progestin-regulated luminal cell and myoepithelial cell-specific responses in mammary organoid culture. Endocrinology 149: 2098-2107.
81. Gudjonsson T, Adriance MC, Sternlicht MD, Petersen OW, Bissell MJ, (2005) Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. J Mammary Gland Biol Neoplasia 10: 261-272.
82. Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, et al. (2000) Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res 60: 4346-4348.
83. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, et al. (2008) Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68: 3645-3654.
84. Berx G, Van Roy F, (2001) The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 3: 289-293.
85. Lombaerts M, van Wezel T, Philippo K, Dierssen JW, Zimmerman RM, et al. (2006) E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer 94: 661-671.
86. Akhtar N, Marlow R, Lambert E, Schatzmann F, Lowe ET, et al. (2009) Molecular dissection of integrin signalling proteins in the control of mammary epithelial development and differentiation. Development 136: 1019-1027.
87. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, et al. (2002) The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111: 29-40.
88. Rucker EB 3rd, Hale AN, Durtschi DC, Sakamoto K, Wagner KU (2011) Forced involution of the functionally differentiated mammary gland by overexpression of the pro-apoptotic protein bax. Genesis 49: 24-35.
89. Feuerhake F, Sigg W, Hofter EA, Dimpfl T, Welsch U, (2000) Immunohistochemical analysis of Bcl-2 and Bax expression in relation to cell turnover and epithelial differentiation markers in the non-lactating human mammary gland epithelium. Cell Tissue Res 299: 47-58.
90. Shay JW, Zou Y, Hiyama E, Wright WE, (2001) Telomerase and cancer. Hum Mol Genet 10: 677-685.
91. Young P, Boussadia O, Berger P, Leone DP, Charnay P, et al. (2002) E-cadherin is required for the correct formation of autotypic adherens junctions of the outer mesaxon but not for the integrity of myelinated fibers of peripheral nerves. Mol Cell Neurosci 21: 341-351.
92. Boussadia O, Kutsch S, Hierholzer A, Delmas V, Kemler R, (2002) E-cadherin is a survival factor for the lactating mouse mammary gland. Mech Dev 115: 53-62.
93. Angeloni SV, Martin MB, Garcia-Morales P, Castro-Galache MD, Ferragut JA, et al. (2004) Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol 180: 497-504.
94. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D, (1988) P53 expression in breast cancer. Int J Cancer 41: 178-183.
95. Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, et al. (1994) p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer 73: 2147-2156.
96. Hynes NE, Stoelzle T, (2009) Key signalling nodes in mammary gland development and cancer: Myc. Breast Cancer Res 11: 210.
97. Stoelzle T, Schwarb P, Trumpp A, Hynes NE, (2009) c-Myc affects mRNA translation, cell proliferation and progenitor cell function in the mammary gland. BMC Biol 7: 63.
98. Kohrmann A, Kammerer U, Kapp M, Dietl J, Anacker J, (2009) Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer 9: 188.
99. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N, (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2: 252-257.
100. Liu Y, West SC, (2002) Distinct functions of BRCA1 and BRCA2 in double-strand break repair. Breast Cancer Res 4: 9-13.
101. Gorski JJ, Kennedy RD, Hosey AM, Harkin DP, (2009) The complex relationship between BRCA1 and ERalpha in hereditary breast cancer. Clin Cancer Res 15: 1514-1518.
102. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, et al. (2007) Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 99: 1683-1694.
103. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, et al. (2006) RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66: 6512-6520.
104. Subramaniam MM, Chan JY, Soong R, Ito K, Ito Y, et al. (2009) RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat 113: 113-121.
105. Clarke RB, Howell A, Anderson E, (1997) Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. Breast Cancer Res Treat 45: 121-133.
106. Laidlaw IJ, Clarke RB, Howell A, Owen AW, Potten CS, et al. (1995) The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology 136: 164-171.
107. McCave EJ, Cass CA, Burg KJ, Booth BW, (2010) The normal microenvironment directs mammary gland development. J Mammary Gland Biol Neoplasia 15: 291-299.
108. Palmieri C, Saji S, Sakaguchi H, Cheng G, Sunters A, et al. (2004) The expression of oestrogen receptor (ER)-beta and its variants, but not ERalpha, in adult human mammary fibroblasts. J Mol Endocrinol 33: 35-50.